WO2007058986A3 - Methodes destinees au diagnostic du trouble depressif majeur et a l'identification d'agents therapeutiques efficaces pour le traitement du trouble depressif majeur - Google Patents

Methodes destinees au diagnostic du trouble depressif majeur et a l'identification d'agents therapeutiques efficaces pour le traitement du trouble depressif majeur Download PDF

Info

Publication number
WO2007058986A3
WO2007058986A3 PCT/US2006/043886 US2006043886W WO2007058986A3 WO 2007058986 A3 WO2007058986 A3 WO 2007058986A3 US 2006043886 W US2006043886 W US 2006043886W WO 2007058986 A3 WO2007058986 A3 WO 2007058986A3
Authority
WO
WIPO (PCT)
Prior art keywords
creb1
promoter
diagnosing
methods
variant
Prior art date
Application number
PCT/US2006/043886
Other languages
English (en)
Other versions
WO2007058986A2 (fr
Inventor
George Zubenko
Original Assignee
Univ Pittsburgh
George Zubenko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh, George Zubenko filed Critical Univ Pittsburgh
Publication of WO2007058986A2 publication Critical patent/WO2007058986A2/fr
Publication of WO2007058986A3 publication Critical patent/WO2007058986A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une méthode permettant de déterminer le risque pour un humain de développer un trouble dépressif majeur ou un trouble associé et une méthode permettant de diagnostiquer un trouble dépressif majeur ou un trouble associé chez un humain. Ces deux méthodes consistent à analyser un prélèvement organique pour y détecter une variation au niveau de la séquence de l'ADN du promoteur d'un gène CREB1. L'invention concerne également des méthodes permettant d'identifier un médicament pouvant traiter le trouble dépressif majeur ou un trouble associé, un animal transgénique comprenant un gène CREB1 lié de manière fonctionnelle à une variante de promoteur CREB1, une séquence d'acide nucléique purifiée ou isolée comprenant une variante de promoteur CREB1 liée de manière fonctionnelle à un gène rapporteur, et une cellule isolée et une lignée cellulaire comprenant un gène lié de manière fonctionnelle à une variante de promoteur CREB1.
PCT/US2006/043886 2005-11-10 2006-11-10 Methodes destinees au diagnostic du trouble depressif majeur et a l'identification d'agents therapeutiques efficaces pour le traitement du trouble depressif majeur WO2007058986A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73609505P 2005-11-10 2005-11-10
US60/736,095 2005-11-10
US74915005P 2005-12-08 2005-12-08
US60/749,150 2005-12-08

Publications (2)

Publication Number Publication Date
WO2007058986A2 WO2007058986A2 (fr) 2007-05-24
WO2007058986A3 true WO2007058986A3 (fr) 2007-11-15

Family

ID=38049181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/043886 WO2007058986A2 (fr) 2005-11-10 2006-11-10 Methodes destinees au diagnostic du trouble depressif majeur et a l'identification d'agents therapeutiques efficaces pour le traitement du trouble depressif majeur

Country Status (1)

Country Link
WO (1) WO2007058986A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158374B1 (en) 2006-09-05 2012-04-17 Ridge Diagnostics, Inc. Quantitative diagnostic methods using multiple parameters
US8440418B2 (en) 2008-11-18 2013-05-14 Ridge Diagnostics, Inc. Metabolic syndrome and HPA axis biomarkers for major depressive disorder
WO2009114627A2 (fr) * 2008-03-12 2009-09-17 Ridge Diagnostics, Inc. Biomarqueurs d'inflammation pour la surveillance de troubles de dépression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197312A1 (en) * 2004-03-03 2005-09-08 Kevin Fitzgerald Transcription factor RNA interference reagents and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197312A1 (en) * 2004-03-03 2005-09-08 Kevin Fitzgerald Transcription factor RNA interference reagents and methods of use thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BLENDY ET AL: "The Role of CREB in Depression and Antidepressant Treatment", BIOLOGICAL PSYCHIATRY, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 59, no. 12, 15 June 2006 (2006-06-15), pages 1144 - 1150, XP005512587, ISSN: 0006-3223 *
COVEN EMILY ET AL: "Cell type-specific regulation of CREB gene expression: Mutational analysis of CREB promoter activity", JOURNAL OF NEUROCHEMISTRY, vol. 71, no. 5, November 1998 (1998-11-01), pages 1865 - 1874, XP002435675, ISSN: 0022-3042 *
PAEZ-PEREDA ET AL: "New drug targets in the signaling pathways activated by antidepressants", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, OXFORD, GB, vol. 29, no. 6, 8 June 2005 (2005-06-08), pages 1010 - 1016, XP005007795, ISSN: 0278-5846 *
SAKAI N, DUMAN RS: "Development and analysis of brain-specific and inducible CREB transgenic mice, using tetracycline regulated gene expression system.", TWENTY-SECOND ANNUAL MEETING OF THE JAPAN NEUROSCIENCE SOCIETY. IN: NEUROSCIENCE RESEARCH, ELSEVIER, SHANNON, IR, vol. 35, 2 December 1999 (1999-12-02), pages S134, XP002435676, ISSN: 0168-0102 *
SCHECHTER ET AL: "Innovative Approaches for the Development of Antidepressant Drugs: Current and Future Strategies", JOURNAL OF THE AMERICAN SOCIETY FOR EXPERIMENTAL NEUROTHERAPEUTICS, XX, XX, vol. 2, no. 4, October 2005 (2005-10-01), pages 590 - 611, XP005321004, ISSN: 1545-5343 *
ZUBENKO G S ET AL: "Genome-wide linkage survey for genetic loci that influence the development of depressive disorders in families with recurrent, early-onset, major depression.", AMERICAN JOURNAL OF MEDICAL GENETICS. PART B, NEUROPSYCHIATRIC GENETICS : THE OFFICIAL PUBLICATION OF THE INTERNATIONAL SOCIETY OF PSYCHIATRIC GENETICS 15 NOV 2003, vol. 123, no. 1, 15 November 2003 (2003-11-15), pages 1 - 18, XP002435674, ISSN: 1552-4841 *
ZUBENKO G S ET AL: "Sequence variations in CREB1 cosegregate with depressive disorders in women.", MOLECULAR PSYCHIATRY, vol. 8, no. 6, 2003, pages 611 - 618, XP002435673, ISSN: 1359-4184 *

Also Published As

Publication number Publication date
WO2007058986A2 (fr) 2007-05-24

Similar Documents

Publication Publication Date Title
ATE549625T1 (de) Verfahren und zusammensetzungen zum nachweis einer zervixerkrankung
WO2009055597A3 (fr) Procédés d'identification d'une liaison génétique
MX2022002458A (es) Metodo de aislamiento de nucleosomas circulantes.
ATE414180T1 (de) Verwendung der gene kir2.3 und drd2 als molekulare marker zur diagnose von schizophrenie
JP2014533949A5 (fr)
WO2007022374A3 (fr) Evaluation de la reponse a une therapie anti-cd21 par genotypage de composants c1q
EA027258B1 (ru) Способ прогнозирования стиля передвижения у лошади и применение указанного способа для отбора лошади для разведения
WO2007058986A3 (fr) Methodes destinees au diagnostic du trouble depressif majeur et a l'identification d'agents therapeutiques efficaces pour le traitement du trouble depressif majeur
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
Quist et al. Identification of a candidate mutation in the COL1A2 gene of a Chow Chow with osteogenesis imperfecta
ATE534902T1 (de) Replikationsproteinn ciz1
JP2011510666A5 (fr)
WO2012122219A3 (fr) Marqueur prédictif de l'efficacité thérapeutique de l'inhibiteur dnmt1, et procédés d'utilisation dudit marqueur
RU2639510C2 (ru) Способ диагностики полиморфизма smc2, ассоциированного с гаплотипом фертильности нн3 крупного рогатого скота
WO2003076950A3 (fr) Procede de tri permettant l'identification de substances protectrices en vue du traitement de maladies neurodegeneratives et/ou ischemiques
JP3491034B2 (ja) 慢性肺気腫を発症するリスクを予測するデータを収集する方法
Sziraki Developing EasySci, a High-Throughput and Low-Cost Single-Cell Genomic Technique, to Study Aging and Alzheimer's Disease in Human and Mouse Brain
WO2006084007A3 (fr) Nouveau gene sous-jacent du site actif i de l'atherosclerose
Nogaj et al. Evaluation of changes in the genetic structure of Hucul horses based on the analysis of I type of genetic markers
EP3321374A1 (fr) Maladies auto-inflammatoires des chiens shar-pei
RU2668829C2 (ru) Способ проведения аллель-специфичной пцр для генотипирования крупного рогатого скота по аллельным вариантам аа, кк и ак гена фермента диацетил-глицерин о-ацетил трансферазы для определения наследуемости жирномолочности
Bovo et al. Whole-genome resequencing reveals signatures of selection in European pig breeds and wild boars
US20080038842A1 (en) SLITRK1 mutations associated with disorders in the OCD spectrum
Albuquerque et al. Comparative transcriptomic analysis of dorsal subcutaneous fat from Portuguese local pig breeds
ATE482289T1 (de) Direkte identifikation und mapping von rna- transkripten

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06837382

Country of ref document: EP

Kind code of ref document: A2